Factor Xa, a trypsin-like serine protease that catalyzes the conversion of prothrombin to thrombin, is located at the crucial intersection of the intrinsic and extrinsic pathways. As a result, it plays a crucial role in the final common pathway of the cascade and has emerged as a key target in the research and development of new anticoagulants. A vital protease in the coagulation process called factor Xa is known to have some of its activity controlled by its interactions with sodium ions and factor Va.
Fibrin, the substance that forms the basis of all blood clots, is produced as a result of an intricate series of enzymatic reactions during blood coagulation. The intrinsic and extrinsic pathways, which make up this cascade's two arms, come together at factor Xa to form the common pathway. Prothrombin is activated by factor Xa to become thrombin, which then catalyzes the transformation of fibrinogen into fibrin.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V0949 | Apixaban (BMS-56224701) | 503612-47-3 | Apixaban (formerlyBMS56224701; BMS 56224701;BMS-56224701; trade name: Eliquis),an approved drug used to treat and prevent the formation of blood clots, is a highly selective, reversible, direct inhibitor of Factor Xa with potential anti-coagulant activity. |
|
V2615 | Edoxaban | 480449-70-5 | Edoxaban (alsoknown as DU-176b; DU176; Lixiana; Savaysa)is a potent, direct-acting, selective, orally bioavailable factor Xa inhibitor used as ananticoagulant drug. |
|
V0950 | Edoxaban tosylate monohydrate (DU-176b) | 1229194-11-9 | Edoxaban tosylate monohydrate(DU-176b;DU-176; trade name Lixiana), the tosylate salt of edoxaban which is a marketed anticoagulant drug,is a potent, selective, orally bioavailable anddirect factor Xa inhibitor with potential anti-coagulant activity. |
|
V21240 | Fondaparinux sodium | 114870-03-0 | Fondaparinux sodium (PENTA; SR-90107A; IC-85158; Arixtra; Xantidar) is a factor Xa inhibitor to form the high affinity binding site for the anti-coagulant factor antithrombin III (ATIII). |
|
V0948 | Rivaroxaban (BAY 59-7939) | 366789-02-8 | Rivaroxaban (BAY59-7939; BAY-59-7939;trade name: Xarelto),an approved anticoagulant drug used to treat and prevent blood clots, is the first orally bioavailable, selective anddirect inhibitor of Factor Xa with potential anti-coagulant activity. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
